# Grove Collaborative Holdings, Inc.: financial statements, quarterly

GROV · NYSE · CIK 1841761 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/grov.md) · [Financials](/companies/grov/financials.md) · [Filings](/companies/grov/filings.md) · [Insiders](/companies/grov/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/grov/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [61.8](/filings/0001628280-24-047657.md) | [59.9 d](/filings/0001628280-25-013839.md) | [53.5](/filings/0001628280-25-025541.md) | [52.1](/filings/0001628280-25-038957.md) | [48.3](/filings/0001841761-25-000048.md) | [49.5 d](/filings/0001841761-26-000010.md) | [43.5](/filings/0001841761-26-000035.md) | [44.0](/filings/0001841761-26-000064.md) | [43.7](/filings/0001841761-25-000048.md) | [42.4 d](/filings/0001841761-26-000010.md) | [36.2](/filings/0001841761-26-000035.md) | [36.6](/filings/0001841761-26-000064.md) |
| Cost of revenue | $m | [28.5](/filings/0001628280-24-047657.md) | [27.3 d](/filings/0001628280-25-013839.md) | [23.8](/filings/0001628280-25-025541.md) | [24.0](/filings/0001628280-25-038957.md) | [22.7](/filings/0001841761-25-000048.md) | [23.6 d](/filings/0001841761-26-000010.md) | [20.5](/filings/0001841761-26-000035.md) | [19.6](/filings/0001841761-26-000064.md) | [20.4](/filings/0001841761-25-000048.md) | [19.9 d](/filings/0001841761-26-000010.md) | [16.4](/filings/0001841761-26-000035.md) | [17.0](/filings/0001841761-26-000064.md) |
| Gross profit | $m | [33.2](/filings/0001628280-24-047657.md) | [32.6 d](/filings/0001628280-25-013839.md) | [29.7](/filings/0001628280-25-025541.md) | [28.1](/filings/0001628280-25-038957.md) | [25.6](/filings/0001841761-25-000048.md) | [25.9 d](/filings/0001841761-26-000010.md) | [23.1](/filings/0001841761-26-000035.md) | [24.4](/filings/0001841761-26-000064.md) | [23.3](/filings/0001841761-25-000048.md) | [22.5 d](/filings/0001841761-26-000010.md) | [19.9](/filings/0001841761-26-000035.md) | [19.6](/filings/0001841761-26-000064.md) |
| Research and development | $m | [3.6](/filings/0001628280-24-047657.md) | [4.6 d](/filings/0001628280-25-013839.md) | [3.6](/filings/0001628280-25-025541.md) | [5.4](/filings/0001628280-25-038957.md) | [4.8](/filings/0001841761-25-000048.md) | [4.6 d](/filings/0001841761-26-000010.md) | [1.8](/filings/0001841761-26-000035.md) | [2.2](/filings/0001841761-26-000064.md) | [1.6](/filings/0001841761-25-000048.md) | [1.9 d](/filings/0001841761-26-000010.md) | [1.4](/filings/0001841761-26-000035.md) | [1.5](/filings/0001841761-26-000064.md) |
| Selling, general and administrative | $m | [29.7](/filings/0001628280-24-047657.md) | [32.1 d](/filings/0001628280-25-013839.md) | [24.6](/filings/0001628280-25-025541.md) | [27.1](/filings/0001628280-25-038957.md) | [24.7](/filings/0001841761-25-000048.md) | [26.7 d](/filings/0001841761-26-000010.md) | [22.0](/filings/0001841761-26-000035.md) | [23.0](/filings/0001841761-26-000064.md) | [21.3](/filings/0001841761-25-000048.md) | [21.2 d](/filings/0001841761-26-000010.md) | [18.2](/filings/0001841761-26-000035.md) | [17.6](/filings/0001841761-26-000064.md) |
| Operating income | $m | [(4.1)](/filings/0001628280-24-047657.md) | [(7.9) d](/filings/0001628280-25-013839.md) | [(0.5)](/filings/0001628280-25-025541.md) | [(6.9)](/filings/0001628280-25-038957.md) | [(6.7)](/filings/0001841761-25-000048.md) | [(8.3) d](/filings/0001841761-26-000010.md) | [(3.5)](/filings/0001841761-26-000035.md) | [(3.5)](/filings/0001841761-26-000064.md) | [(2.7)](/filings/0001841761-25-000048.md) | [(1.6) d](/filings/0001841761-26-000010.md) | [(0.9)](/filings/0001841761-26-000035.md) | [(0.8)](/filings/0001841761-26-000064.md) |
| Interest expense | $m | [4.1](/filings/0001628280-23-038302.md) | [4.2 d](/filings/0001628280-24-012257.md) | [4.1](/filings/0001628280-24-023259.md) | [4.1](/filings/0001628280-25-038957.md) | [2.9](/filings/0001841761-25-000048.md) | [1.6 d](/filings/0001841761-26-000010.md) | [0.3](/filings/0001841761-26-000035.md) | [0.3](/filings/0001841761-26-000064.md) | [0.3](/filings/0001841761-25-000048.md) | [0.3 d](/filings/0001841761-26-000010.md) | [0.3](/filings/0001841761-26-000035.md) | [0.3](/filings/0001841761-26-000064.md) |
| Income tax | $m | [0.0](/filings/0001628280-24-047657.md) | [0.0 d](/filings/0001628280-25-013839.md) | [0.0](/filings/0001628280-25-025541.md) | [0.0](/filings/0001628280-25-038957.md) | [0.0](/filings/0001841761-25-000048.md) | [0.0 d](/filings/0001841761-26-000010.md) | [0.0](/filings/0001841761-26-000035.md) | [0.0](/filings/0001841761-26-000064.md) | [0.0](/filings/0001841761-25-000048.md) | [0.0 d](/filings/0001841761-26-000010.md) | [0.0](/filings/0001841761-26-000035.md) | [0.0](/filings/0001841761-26-000064.md) |
| Net income | $m | [(9.8)](/filings/0001628280-24-047657.md) | [(9.5) d](/filings/0001628280-25-013839.md) | [(3.4)](/filings/0001841761-25-000048.md) | [(10.1)](/filings/0001841761-25-000048.md) | [(1.3)](/filings/0001841761-25-000048.md) | [(12.6) d](/filings/0001841761-26-000010.md) | [(3.5)](/filings/0001841761-26-000064.md) | [(3.6)](/filings/0001841761-26-000064.md) | [(3.0)](/filings/0001841761-25-000048.md) | [(1.6) d](/filings/0001841761-26-000010.md) | [(1.0)](/filings/0001841761-26-000064.md) | [(0.9)](/filings/0001841761-26-000064.md) |
| Diluted EPS | $ per share | [(0.31)](/filings/0001628280-24-047657.md) | not reported | [(0.10)](/filings/0001628280-25-025541.md) | [(0.28)](/filings/0001628280-25-038957.md) | [(0.04)](/filings/0001841761-25-000048.md) | not reported | [(0.10)](/filings/0001841761-26-000035.md) | [(0.10)](/filings/0001841761-26-000064.md) | [(0.08)](/filings/0001841761-25-000048.md) | not reported | [(0.03)](/filings/0001841761-26-000035.md) | [(0.03)](/filings/0001841761-26-000064.md) |
| Basic EPS | $ per share | [(0.31)](/filings/0001628280-24-047657.md) | not reported | [(0.10)](/filings/0001628280-25-025541.md) | [(0.28)](/filings/0001628280-25-038957.md) | [(0.04)](/filings/0001841761-25-000048.md) | not reported | [(0.10)](/filings/0001841761-26-000035.md) | [(0.10)](/filings/0001841761-26-000064.md) | [(0.08)](/filings/0001841761-25-000048.md) | not reported | [(0.03)](/filings/0001841761-26-000035.md) | [(0.03)](/filings/0001841761-26-000064.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [86.1](/filings/0001628280-24-047657.md) | [86.4](/filings/0001628280-25-013839.md) | [77.8](/filings/0001628280-25-025541.md) | [78.8](/filings/0001628280-25-038957.md) | [50.8](/filings/0001841761-25-000048.md) | [19.6](/filings/0001841761-26-000010.md) | [9.6](/filings/0001841761-26-000035.md) | [10.0](/filings/0001841761-26-000064.md) | [8.9](/filings/0001841761-25-000048.md) | [8.5](/filings/0001841761-26-000064.md) | [7.2](/filings/0001841761-26-000035.md) | [8.3](/filings/0001841761-26-000064.md) |
| Current assets | $m | [130](/filings/0001628280-23-038302.md) | [124](/filings/0001628280-25-013839.md) | [116](/filings/0001628280-24-023259.md) | [113](/filings/0001628280-24-036814.md) | [81.8](/filings/0001628280-24-047657.md) | [44.9](/filings/0001841761-26-000010.md) | [38.2](/filings/0001628280-25-025541.md) | [36.8](/filings/0001628280-25-038957.md) | [34.5](/filings/0001841761-25-000048.md) | [34.7](/filings/0001841761-26-000064.md) | [33.5](/filings/0001841761-26-000035.md) | [33.9](/filings/0001841761-26-000064.md) |
| Total assets | $m | [161](/filings/0001628280-23-038302.md) | [151](/filings/0001628280-25-013839.md) | [138](/filings/0001628280-24-023259.md) | [132](/filings/0001628280-24-036814.md) | [105](/filings/0001628280-24-047657.md) | [65.0](/filings/0001841761-26-000010.md) | [59.8](/filings/0001628280-25-025541.md) | [57.8](/filings/0001628280-25-038957.md) | [54.6](/filings/0001841761-25-000048.md) | [53.1](/filings/0001841761-26-000064.md) | [51.1](/filings/0001841761-26-000035.md) | [50.8](/filings/0001841761-26-000064.md) |
| Current liabilities | $m | [37.7](/filings/0001628280-23-038302.md) | [35.0](/filings/0001628280-25-013839.md) | [28.9](/filings/0001628280-24-023259.md) | [29.2](/filings/0001628280-24-036814.md) | [39.6](/filings/0001628280-24-047657.md) | [27.1](/filings/0001841761-26-000010.md) | [25.8](/filings/0001628280-25-025541.md) | [27.6](/filings/0001628280-25-038957.md) | [27.5](/filings/0001841761-25-000048.md) | [27.7](/filings/0001841761-26-000064.md) | [26.2](/filings/0001841761-26-000035.md) | [26.9](/filings/0001841761-26-000064.md) |
| Total liabilities | $m | [137](/filings/0001628280-23-038302.md) | [133](/filings/0001628280-25-013839.md) | [120](/filings/0001628280-24-023259.md) | [121](/filings/0001628280-24-036814.md) | [78.8](/filings/0001628280-24-047657.md) | [48.8](/filings/0001841761-26-000010.md) | [46.7](/filings/0001628280-25-025541.md) | [47.1](/filings/0001628280-25-038957.md) | [46.0](/filings/0001841761-25-000048.md) | [45.3](/filings/0001841761-26-000064.md) | [43.7](/filings/0001841761-26-000035.md) | [43.5](/filings/0001841761-26-000064.md) |
| Long-term debt | $m | [70.8](/filings/0001628280-23-038302.md) | [71.7](/filings/0001628280-25-013839.md) | [72.5](/filings/0001628280-24-023259.md) | [73.4](/filings/0001628280-24-036814.md) | [22.2](/filings/0001628280-24-047657.md) | [7.5](/filings/0001841761-26-000010.md) | [7.5](/filings/0001628280-25-025541.md) | [6.8](/filings/0001628280-25-038957.md) | [6.6](/filings/0001841761-25-000048.md) | [6.7](/filings/0001841761-26-000064.md) | [7.5](/filings/0001841761-26-000035.md) | [7.5](/filings/0001841761-26-000064.md) |
| Current portion of debt | $m | [0.0](/filings/0001628280-23-038302.md) | [0.0](/filings/0001628280-24-047657.md) | not reported | not reported | [10.0](/filings/0001628280-24-047657.md) | [0.0](/filings/0001841761-26-000010.md) | not reported | [0.7](/filings/0001628280-25-038957.md) | [0.9](/filings/0001841761-25-000048.md) | [0.8](/filings/0001841761-26-000064.md) | [0.0](/filings/0001841761-26-000035.md) | [0.0](/filings/0001841761-26-000064.md) |
| Shareholders' equity | $m | [14.1](/filings/0001628280-24-047657.md) | [8.1](/filings/0001841761-26-000010.md) | [7.5](/filings/0001841761-25-000048.md) | [0.7](/filings/0001841761-25-000048.md) | [1.5](/filings/0001841761-25-000048.md) | [(8.5)](/filings/0001841761-26-000064.md) | [(11.6)](/filings/0001841761-26-000064.md) | [(14.0)](/filings/0001841761-26-000064.md) | [(16.1)](/filings/0001841761-25-000048.md) | [(17.0)](/filings/0001841761-26-000064.md) | [(17.4)](/filings/0001841761-26-000064.md) | [(17.5)](/filings/0001841761-26-000064.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent, us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(3.5) d](/filings/0001628280-24-047657.md) | [1.1 d](/filings/0001628280-25-013839.md) | [(12.4)](/filings/0001628280-25-025541.md) | [1.6 d](/filings/0001628280-25-038957.md) | [0.8 d](/filings/0001841761-25-000048.md) | [0.3 d](/filings/0001841761-26-000010.md) | [(6.9)](/filings/0001841761-26-000035.md) | [1.0 d](/filings/0001841761-26-000064.md) | [(1.0) d](/filings/0001841761-25-000048.md) | [(0.0) d](/filings/0001841761-26-000010.md) | [(0.7)](/filings/0001841761-26-000035.md) | [1.3 d](/filings/0001841761-26-000064.md) |
| Capital expenditure | $m | [0.8 d](/filings/0001628280-24-047657.md) | [0.6 d](/filings/0001628280-25-013839.md) | [0.5](/filings/0001628280-25-025541.md) | [0.4 d](/filings/0001628280-25-038957.md) | [0.5 d](/filings/0001841761-25-000048.md) | [0.4 d](/filings/0001841761-26-000010.md) | [0.5](/filings/0001841761-26-000035.md) | [0.4 d](/filings/0001841761-26-000064.md) | [0.2 d](/filings/0001841761-25-000048.md) | [0.0 d](/filings/0001841761-26-000010.md) | [0.3](/filings/0001841761-26-000035.md) | [0.2 d](/filings/0001841761-26-000064.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [33.2](/filings/0001628280-23-038302.md) | [33.7](/filings/0001628280-24-023259.md) | [34.3](/filings/0001628280-24-036814.md) | [35.3](/filings/0001628280-24-047657.md) | [36.3](/filings/0001628280-25-025541.md) | [36.8](/filings/0001628280-25-038957.md) | [37.3](/filings/0001841761-25-000048.md) | [38.2](/filings/0001841761-26-000035.md) | [38.8](/filings/0001841761-26-000064.md) | [39.4](/filings/0001841761-25-000048.md) | [40.1](/filings/0001841761-26-000035.md) | [40.6](/filings/0001841761-26-000064.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 42,701,046 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001841761-26-000064.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.